Drug Trial Radar · NCT05787587
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
216
Planned (sponsor's estimate)
Start
Apr 18, 2023
Primary completion
Oct 2026
Study completion May 2027
Sponsor
- Lead sponsor
- IDEAYA BiosciencesIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Mar 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Conditions
- Advanced or Metastatic Solid Tumors
- Breast Cancer
- Ovarian Cancer
- Prostate Cancer
- Endometrial Cancer
- Colorectal Cancer
- Head and Neck Cancers
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- NSCLC
Interventions
IDE-161Drug
Oral Medication
PembrolizumabDrug
Intravenous Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDETime frame: Approximately 2 years
- Part 2 (Dose Expansion): To further assess the safety and tolerability of IDE monotherapy and in combination with pembrolizumab at the RDETime frame: Approximately 4 years
- Part 2 (Dose Expansion): To evaluate preliminary anti-tumor activity of IDE161 monotherapy or in combination with pembrolizumabTime frame: Approximately 4 years
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth Research Institute
Phoenix, Arizona
The Angeles Clinic
Los Angeles, California
Hoag Memorial Hospital
Newport Beach, California
California Pacific Medical Center
San Francisco, California
Sarah Cannon Research Institute
Denver, Colorado
Yale University
New Haven, Connecticut
Orlando Health
Orlando, Florida
Emory University
Atlanta, Georgia
OSF St Francis Medical Center
Peoria, Illinois
Indiana University
Indianapolis, Indiana
Dana Faber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Columbia University Medical Center
New York, New York
Weil Cornell University
New York, New York
Sarah Cannon Research Institute - Oklahoma University
Oklahoma City, Oklahoma
University of Pennsylvania
Philadelphia, Pennsylvania
Sarah Cannon Research Institute - Thomas Jefferson University
Philadelphia, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
MD Anderson
Houston, Texas
NEXT Oncology
Irving, Texas
NEXT Oncology
San Antonio, Texas
START Mountain Region
West Valley City, Utah
NEXT Oncology
Fairfax, Virginia
Swedish Cancer Institute
Seattle, Washington
University of Wisconsin
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.